Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06282978
Title Phase II Study of Elranatamab as Single Agent for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors PETHEMA Foundation
Age Groups: adult | senior
Covered Countries ESP

No variant requirements are available.